

Reference:	FOI.20337.26
Subject:	Biologic medicines in Dermatology
Date of Request:	1 May 2026

Requested:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Apremilast - Otezla
 - Apremilast generic
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - Deucravacitinib
 - Dimethyl fumarate
 - Etanercept - Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar
 - Omalizumab
 - Spesolimab

2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:
 - Adalimumab - Humira
 - Adalimumab Biosimilar
 - Bimekizumab
 - Certolizumab
 - Infliximab - Remicade
 - Infliximab Biosimilar
 - Secukinumab
 - Ustekinumab - Stelara
 - Ustekinumab Biosimilar

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of Dermatology patients treated for any medical condition, with the listed medications, during the period 1 February to 30 April 2026.

Medication	Number
Adalimumab - Humira	*
Adalimumab Biosimilar	95
Apremilast - Otezla	0
Apremilast generic	10
Bimekizumab	*
Brodalumab	*
Certolizumab	0
Deucravacitinib	0
Dimethyl fumarate	*
Etanercept - Enbrel	0
Etanercept Biosimilar	*
Guselkumab	*
Infliximab - Remicade	0
Infliximab Biosimilar	0
Ixekizumab	0
Risankizumab	38
Secukinumab	41
Tildrakizumab	*
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	27
Omalizumab	17
Spesolimab	0

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

- The UHB provides within the table below the number of Dermatology patients treated for Hidradenitis Suppurativa (HS), with the listed medications, during the period 1 February to 30 April 2026.

Medication	Number
Adalimumab - Humira	0
Adalimumab Biosimilar	13
Bimekizumab	0
Certolizumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	0
Secukinumab	6
Ustekinumab - Stelara	0
Ustekinumab Biosimilar	0